common.study.topics.clinical

Brain Connectivity in Treatment Resistant Depression

common.study.values.description

“Structural and Functional Connectivity of Brainstem Monoamine Pathways in Treatment Resistant Depression”

Study TRD subjects' resistance to at least 2 different antidepressants, we hypothesize that because of their significant depression and treatment resistant status they are most likely to exhibit BSMN pathway abnormalities.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Drug - Monoamine Oxidase Inhibitor (MAOI)

Monoamine Oxidase Inhibitor

participant.views.study.view.additional

participant.views.study.view.scientific-title

Structural and Functional Connectivity of Brainstem Monoamine Pathways in Treatment Resistant Depression

common.study.values.clinical-trial-id

NCT03109717

participant.views.study.view.id

mbk0Ed